Novo Nordisk Lifts 2026 Outlook Again as Wegovy Pill Sales Miss Expectations
Updated
Updated · Bloomberg · Aug 4
Novo Nordisk Lifts 2026 Outlook Again as Wegovy Pill Sales Miss Expectations
3 articles · Updated · Bloomberg · Aug 4
Summary
Novo Nordisk said 2026 sales and profit will fall no more than 6% at constant exchange rates, improving from an earlier forecast for declines of as much as 12%.
US-listed shares still fell more than 5% after sales of the new Wegovy weight-loss pill came in below Wall Street expectations, undercutting enthusiasm around the obesity franchise.
The company raised guidance for the second time this year on a stronger outlook for its obesity and diabetes drugs, even as investors focused on the pill's weaker-than-expected showing.
The mixed update highlights the pressure on Novo to prove newer Wegovy formats can sustain growth as competition and pricing scrutiny intensify in the US obesity market.